Haloperidol Esteve (Haloperidol)

Haloperidol Esteve is indicated for several acute psychiatric conditions where rapid control of symptoms is required, and it is often used in inpatient or emergency environments.

• Schizophrenia, especially during acute exacerbations or when oral therapy is not feasible.
• Acute psychotic episodes related to bipolar disorder or major depressive disorder with psychotic features.
• Severe agitation, aggression, or violent behavior requiring rapid calming in emergency or psychiatric units.
• Pre‑operative sedation for patients at risk of delirium or postoperative psychosis.
• Management of hyperactive delirium in intensive care or postoperative settings.

The safety profile of Haloperidol Esteve includes a range of adverse effects that vary in frequency and severity; patients should be monitored regularly for both common and potentially serious reactions.

Common

• Drowsiness or sedation, which may affect alertness and coordination.
• Extrapyramidal symptoms such as tremor, muscle rigidity, akathisia, or dystonia.
• Dry mouth, increased salivation, or other anticholinergic‑like effects.
• Constipation, abdominal discomfort, or reduced gastrointestinal motility.

Serious

• Neuroleptic malignant syndrome, a rare but potentially fatal reaction characterized by fever, muscle rigidity, and autonomic instability.
• Cardiac arrhythmias, including QT‑interval prolongation and torsades de pointes, especially in patients with pre‑existing heart conditions.
• Severe hypotension, syncope, or sudden loss of consciousness.

When prescribing Haloperidol Esteve, clinicians should consider several precautionary measures to minimize risks and ensure appropriate use.

• Assess patient history for cardiovascular disease, electrolyte imbalances, or prolonged QT interval before initiating therapy.
• Use the lowest effective dose and limit duration, particularly in elderly patients, to reduce the risk of extrapyramidal symptoms.
• Monitor for signs of neuroleptic malignant syndrome, especially during the first few days of treatment.
• Evaluate liver and renal function periodically, as impairment may affect drug clearance.
• Exercise caution in patients with a history of seizures, Parkinson’s disease, or severe depression.
• Avoid abrupt discontinuation to prevent withdrawal or rebound psychosis.

Haloperidol Esteve can interact with other medications, altering its efficacy or increasing the likelihood of adverse effects; careful review of a patient’s drug regimen is essential.

Avoid

• Use with other dopamine antagonists or high‑potency antipsychotics, which may worsen extrapyramidal effects.
• Combine with QT‑prolonging drugs (e.g., certain antiarrhythmics, macrolide antibiotics) because of increased arrhythmia risk.
• Strong CYP3A4 inhibitors (ketoconazole, clarithromycin) that raise haloperidol levels.

Use with caution

• CYP2D6 substrates (metoprolol, codeine) as haloperidol may alter their metabolism.
• CNS depressants such as benzodiazepines or opioids, which can increase sedation.
• Lithium, because combined use may heighten neurotoxicity risk.